DelveInsight’s ‘Excessive Daytime Sleepiness Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and Excessive Daytime Sleepiness Pipeline therapies in various stages of Excessive Daytime Sleepiness clinical trial development, major pharmaceutical Excessive Daytime Sleepiness Companies are working to advance the Excessive Daytime Sleepiness pipeline space and future growth potential of the Excessive Daytime Sleepiness pipeline domain.
For Excessive Daytime Sleepiness emerging drugs, the Excessive Daytime Sleepiness pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and Mechanism of Action. The Excessive Daytime Sleepiness pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Excessive Daytime Sleepiness Pipeline Report
- Over 10+ Excessive Daytime Sleepiness companies are evaluating 10+ Excessive Daytime Sleepiness pipeline therapies in various stages of development, and their anticipated acceptance in the Excessive Daytime Sleepiness market would significantly increase market revenue.
- The leading Excessive Daytime Sleepiness Companies are working to develop candidates to improve Excessive Daytime Sleepiness treatment scenario includes Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, Axsome Therapeutics, and others.
- Promising Excessive Daytime Sleepiness Pipeline Therapies includes BEN-2001, FT218, AXS-12 (Reboxetine), Xywav (JZP-258) for EDS in IH, Wakix (Pitolisant) for EDS in OSA, and others.
- The Excessive Daytime Sleepiness companies and academics are working to assess challenges and seek opportunities that could influence Excessive Daytime Sleepiness R&D. The Excessive Daytime Sleepiness pipeline therapies under development are focused on novel approaches to treat/improve Excessive Daytime Sleepiness.
Request a sample and discover the recent breakthroughs happening in Excessive Daytime Sleepiness pipeline landscape @ Excessive Daytime Sleepiness Pipeline Outlook Report
Excessive Daytime Sleepiness Overview
Excessive daytime sleepiness is not a condition in itself but a symptom of different conditions. Any condition that restrains an individual from getting good sleep at night can cause excessive daytime sleepiness. The common causes for excessive daytime sleepiness include sleep apnea (a potentially serious condition with abnormal breathing pattern during night), RLS (restless leg syndrome), depression, hypersomnia, and narcolepsy. Hypersomnia and narcolepsy have some similar characteristics. Both the condition involves excessive daytime sleepiness but narcolepsy is rare and more severe with sudden and uncontrollable sleeps, often at inconvenient times. People with narcolepsy also have greater nighttime sleep disturbance than those with hypersomnia, resulting in reduced sleep quality.
Excessive Daytime Sleepiness Emerging Drugs Profile
- Pentetrazol: Balance Therapeutics
Balance Therapeutics’ lead drug candidate, Pentetrazol is a small molecule in development for the treatment of excessive daytime sleepiness due to narcolepsy. The drug has demonstrated good efficacy in its Phase I clinical trials. The drug is a CNS (central nervous system) convulsant that bind to the picrotoxin site of GABA (A) receptor.
- TAK 925: Takeda Pharmaceuticals
Takeda’s “breakthrough” drug TAK 925 is currently being evaluated for the treatment of excessive daytime sleepiness due to hypersomnia as well as narcolepsy. The drug has been designated with orphan drug status for narcolepsy. It is an orexin receptor type-2 agonist which plays an important role in the regulation of sleep and wakefulness.
Find out more about the Excessive Daytime Sleepiness Diagnosis and Treatment of patients @ Excessive Daytime Sleepiness Ongoing Clinical Trials Analysis
Excessive Daytime Sleepiness Companies and Therapies
- BenevolentAI Bio: BEN-2001
- Theranexus: FT218
- Bioprojet Pharma: AXS-12 (Reboxetine)
- Avadel Pharmaceuticals: Xywav (JZP-258) for EDS in IH
- Jazz Pharmaceuticals: Wakix (Pitolisant) for EDS in OSA
Excessive Daytime Sleepiness Pipeline Therapeutics Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small Molecule
- Product Type
Discover more about the list of FDA-approved drugs for Excessive Daytime Sleepiness @ Excessive Daytime Sleepiness Treatment Landscape
Scope of the Excessive Daytime Sleepiness Pipeline Report
- Coverage- Global
- Excessive Daytime Sleepiness Companies- Balance Therapeutics, Takeda Pharmaceuticals (NYSE: TAK), Benevolent AI Bio, Avadel Pharmaceuticals (NYSE: AVDL), Axsome Therapeutics (NYSE: AXSM), and others
- Excessive Daytime Sleepiness Pipeline Therapies- BEN-2001, FT218, AXS-12 (Reboxetine), Xywav (JZP-258) for EDS in IH, Wakix (Pitolisant) for EDS in OSA, and others.
- Excessive Daytime Sleepiness Pipeline Segmentation: Phases, Molecule Type, Product Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for Excessive Daytime Sleepiness Emerging Therapies and Ongoing Clinical Trials; visit @ Excessive Daytime Sleepiness Emerging Therapies and Companies
Table of Content
- Introduction
- Excessive Daytime Sleepiness Executive Summary
- Excessive Daytime Sleepiness: Overview
- Excessive Daytime Sleepiness Pipeline Therapeutics
- Excessive Daytime Sleepiness Therapeutic Assessment
- Excessive Daytime Sleepiness – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Excessive Daytime Sleepiness Collaboration Deals
- Mid Stage Products (Phase II)
- Pentetrazol: Balance Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- TAK 925: Takeda Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Excessive Daytime Sleepiness Key Companies
- Excessive Daytime Sleepiness Key Products
- Excessive Daytime Sleepiness- Unmet Needs
- Excessive Daytime Sleepiness- Market Drivers and Barriers
- Excessive Daytime Sleepiness- Future Perspectives and Conclusion
- Excessive Daytime Sleepiness Analyst Views
- Excessive Daytime Sleepiness Key Companies
- Appendix
For further information on the Excessive Daytime Sleepiness Pipeline therapeutics, reach out @ Excessive Daytime Sleepiness Market Drivers and Barriers
Latest Pharmaceuticals Market Research Reports 2023 by DelveInsight
Technical Due Diligence Firms | Vital Sign Monitors Devices Market | Stem Cell Market | Anastomosis Devices Market | Asperger Syndrome Market | B-Cell Maturation Antigen Targeted Therapies Market | UK Healthcare Report | Oncolytic Virus Cancer Therapy Pipeline | Shingles Market
Latest Blogs by DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com